keyword
https://read.qxmd.com/read/38584488/mesothelioma-of-uncertain-malignant-potential-mump-of-the-tunica-vaginalis-proposal-for-reclassification-as-complex-mesothelial-tumor-of-the-tunica-vaginalis
#21
JOURNAL ARTICLE
Sounak Gupta, John C Cheville
No abstract text is available yet for this article.
April 8, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38583514/surgical-resection-for-pleural-mesothelioma-is-it-all-about-patient-selection
#22
JOURNAL ARTICLE
Valerie W Rusch
No abstract text is available yet for this article.
April 5, 2024: Annals of Thoracic Surgery
https://read.qxmd.com/read/38583133/patients-with-mesothelioma-and-their-carer-s-experience-of-diet-and-appetite-a-qualitative-insight-from-the-help-meso-study
#23
JOURNAL ARTICLE
Lorelle L Dismore, Leah L Taylor, Avinash Aujayeb, Christopher Hurst, Katherine Swainston
BACKGROUND: People living with mesothelioma have a high symptom burden that can affect dietary intake and the development of malnutrition, subsequently impacting on patient-related and treatment outcomes. The present study aimed to develop a better understanding of the experiences of diet and appetite in people living with mesothelioma and their informal carers. METHODS: Twenty-three participants took part in semistructured interviews including 12 people living with mesothelioma (10 pleural and 2 peritoneal) aged 56-83 years and 12 informal carers, predominantly their spouses...
April 7, 2024: Journal of Human Nutrition and Dietetics: the Official Journal of the British Dietetic Association
https://read.qxmd.com/read/38583132/the-presence-of-erionite-in-north-american-geologies-and-the-estimated-mesothelioma-potency-by-region
#24
JOURNAL ARTICLE
Michael E Stevens, Dennis J Paustenbach, Noah J Lockhart, Dalton E Busboom, Blake M Deckard, David W Brew
OBJECTIVE: Erionite is a naturally occurring fibrous mineral found in soils in some geographical regions. Known for its potency for causing mesothelioma in the Cappadocia region of Turkey, the erionite fiber has attracted interest in the United States due to its presence in a band of rock that extends from Mexico to Montana. There are few toxicology studies of erionite, but all show it to have unusually high chronic toxicity. Despite its high potency compared to asbestos fibers, erionite has no occupational or environmental exposure limits...
April 7, 2024: Inhalation Toxicology
https://read.qxmd.com/read/38582547/immunotherapy-is-a-good-standard-option-for-patients-with-malignant-pleural-mesothelioma-despite-the-real-world-results-from-australia
#25
EDITORIAL
Illaa Smesseim, Paul Baas
No abstract text is available yet for this article.
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582546/based-on-the-real-world-results-from-australia-immunotherapy-is-not-a-good-option-for-patients-with-mesothelioma
#26
EDITORIAL
Steven G Gray, Tomer Meirson, Luciano Mutti
No abstract text is available yet for this article.
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38579831/epr24-122-mesothelioma-trends-in-palliative-care-utilization-in-hospitalized-patients-a-national-inpatient-sample-nis-study-2016-2020
#27
JOURNAL ARTICLE
Sangam Sangam, Marco Bermudez, Francisco Gallegos Koyner, Tripti Jain, Shorabh Sharma, Sorab Gupta
No abstract text is available yet for this article.
April 5, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38568257/mesothelioma-morphologic-and-immunohistochemical-findings
#28
REVIEW
Andrew Churg
This paper reviews some basic and some new concepts in the diagnosis of mesothelioma. The term "malignant mesothelioma" is no longer recommended; rather, any tumor labeled "mesothelioma" is presumed to be malignant. Clinical and radiologic information is very useful in the diagnosis of mesothelioma; in particular, nodular pleural thickening on CT is usually a marker of malignancy. The literature on markers that separate mesotheliomas from metastatic carcinomas has become very complex and frequently misleading, with many recommended markers actually demonstrating poor specificity...
April 3, 2024: Pathologie (Heidelb)
https://read.qxmd.com/read/38567597/prognostic-significance-of-inflammation-scores-in-malignant-mesothelioma
#29
JOURNAL ARTICLE
E Mutlu, M Inanc
OBJECTIVE: The relationship between inflammatory markers and survival in many cancers has been investigated previously. Inflammatory markers may also offer the possibility of predicting surveillance in patients with malignant mesothelioma. Our study seeks to enhance comprehension of how variables such as the nutritional status and inflammation indices of malignant mesothelioma patients impact the disease's progression and prognosis. PATIENTS AND METHODS: This study included patients who were treated at the Erciyes University Medical Oncology Clinic between 2010 and 2022 and diagnosed with malignant mesothelioma...
March 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38565920/direct-and-selective-pharmacological-disruption-of-the-yap-tead-interface-by-iag933-inhibits-hippo-dependent-and-ras-mapk-altered-cancers
#30
JOURNAL ARTICLE
Emilie A Chapeau, Laurent Sansregret, Giorgio G Galli, Patrick Chène, Markus Wartmann, Thanos P Mourikis, Patricia Jaaks, Sabrina Baltschukat, Ines A M Barbosa, Daniel Bauer, Saskia M Brachmann, Clara Delaunay, Claire Estadieu, Jason E Faris, Pascal Furet, Stefanie Harlfinger, Andreas Hueber, Eloísa Jiménez Núñez, David P Kodack, Emeline Mandon, Typhaine Martin, Yannick Mesrouze, Vincent Romanet, Clemens Scheufler, Holger Sellner, Christelle Stamm, Dario Sterker, Luca Tordella, Francesco Hofmann, Nicolas Soldermann, Tobias Schmelzle
The YAP-TEAD protein-protein interaction mediates YAP oncogenic functions downstream of the Hippo pathway. To date, available YAP-TEAD pharmacologic agents bind into the lipid pocket of TEAD, targeting the interaction indirectly via allosteric changes. However, the consequences of a direct pharmacological disruption of the interface between YAP and TEADs remain largely unexplored. Here, we present IAG933 and its analogs as potent first-in-class and selective disruptors of the YAP-TEAD protein-protein interaction with suitable properties to enter clinical trials...
April 2, 2024: Nature Cancer
https://read.qxmd.com/read/38562821/nonpathogenic-e-coli-engineered-to-surface-display-cytokines-as-a-new-platform-for-immunotherapy
#31
Rizwan Romee, Shaobo Yang, Michal Sheffer, Isabel Kaplan, Zongqi Wang, Mubin Tarannum, Khanhlinh Dinh, Yasmin Abdulhamid, Roman Shapiro, Rebecca Porter, Robert Soiffer, Jerome Ritz, John Koreth, Yun Wei, Peiru Chen, Ke Zhang, Valeria Márquez-Pellegrin, Shanna Bonanno, Neel Joshi, Ming Guan, Mengdi Yang, Deng Li, Chiara Bellini, Jianzhu Chen, Catherine Wu, David Barbie, Jiahe Li
Given the safety, tumor tropism, and ease of genetic manipulation in non-pathogenic Escherichia coli ( E. coli ), we designed a novel approach to deliver biologics to overcome poor trafficking and exhaustion of immune cells in the tumor microenvironment, via the surface display of key immune-activating cytokines on the outer membrane of E. coli K-12 DH5α. Bacteria expressing murine decoy-resistant IL18 mutein (DR18) induced robust CD8 + T and NK cell-dependent immune responses leading to dramatic tumor control, extending survival, and curing a significant proportion of immune-competent mice with colorectal carcinoma and melanoma...
March 22, 2024: Research Square
https://read.qxmd.com/read/38561242/oncolytic-adenoviruses-and-immunopeptidomics-a%C3%A2-convenient-marriage
#32
JOURNAL ARTICLE
Marc Garcia-Moure, Andrew G Gillard, Marta M Alonso, Juan Fueyo, Candelaria Gomez-Manzano
Oncolytic viruses (OVs) are biological therapeutic agents that selectively destroy cancer cells while sparing normal healthy cells. Besides direct oncolysis, OV infection induces a proinflammatory shift in the tumor microenvironment and the release of tumor-associated antigens (TAAs) that might induce an anti-tumor immunity. Due to their immunostimulatory effect, OVs have been explored for cancer vaccination against specific TAAs. However, this approach usually requires genetic modification of the virus and the production of a new viral vector for each target, which is difficult to implement for low prevalent antigens...
April 1, 2024: Molecular Oncology
https://read.qxmd.com/read/38556354/reversible-and-monitorable-nephrotoxicity-in-rats-by-the-novel-potent-transcriptional-enhanced-associate-domain-tead-inhibitor-k-975
#33
JOURNAL ARTICLE
Hironori Otsuki, Takeshi Uemori, Yohei Inai, Yui Suzuki, Tetsuro Araki, Ken-Ichiro Nan-Ya, Kouichi Yoshinari
The Hippo pathway plays an important role in the growth, development, and regeneration of cells and organs. Transcriptional enhanced associate domain (TEAD), a transcription activator of the Hippo pathway, forms the complex with a transcriptional coactivator yes-associated protein (YAP) or a transcriptional coactivator PDZ-binding motif (TAZ). Their excessive activations are involved in carcinogenesis such as malignant pleural mesothelioma (MPM), and thus inhibition of the TEAD complex is expected to have potent anticancer activity against MPM...
2024: Journal of Toxicological Sciences
https://read.qxmd.com/read/38555809/establishing-mesothelioma-patient-derived-organoid-models-from-malignant-pleural-effusions
#34
JOURNAL ARTICLE
Ashleigh J Hocking, Lauren A Mortimer, Alexandra L Farrall, Prudence A Russell, Sonja Klebe
OBJECTIVES: Pleural mesothelioma is a cancer arising in the cells that line the lungs and chest wall with poor survival and poor response to first-line therapy. Organoid models of cancer can faithfully recapitulate the genetic and histopathological characteristics of individualized tumors and have potential to be used for precision medicine, however methods of establishing patient-derived mesothelioma organoids have not been well established in the published literature. MATERIALS AND METHODS: Long-term mesothelioma patient-derived organoids were established from ten malignant pleural effusion fluids...
March 28, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38552427/combining-bnct-with-carbonic-anhydrase-inhibition-for-mesothelioma-treatment-synthesis-in-vitro-in-vivo-studies-of-ureidosulfamido-carboranes
#35
JOURNAL ARTICLE
Alberto Lanfranco, Sahar Rakhshan, Diego Alberti, Polyssena Renzi, Ayda Zarechian, Nicoletta Protti, Saverio Altieri, Simonetta Geninatti Crich, Annamaria Deagostino
Mesothelioma is a malignant neoplasm of mesothelial cells caused by exposure to asbestos. The average survival time after diagnosis is usually nine/twelve months. A multi-therapeutic approach is therefore required to treat and prevent recurrence. Boronated derivatives containing a carborane cage, a sulfamido group and an ureido functionality (CA-USF) have been designed, synthesised and tested, in order to couple Boron Neutron Capture Therapy (BNCT) and the inhibition of Carbonic Anhydrases (CAs), which are overexpressed in many tumours...
March 26, 2024: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/38547377/pleural-mesothelioma-in-situ-a-comprehensive-review
#36
JOURNAL ARTICLE
Federica Danuzzo, Federico Raveglia, Francesca Spinelli, Chiara Maria Sibilia, Enrico Cassina, Lidia Libretti, Emanuele Pirondini, Antonio Tuoro, Francesca Bono, Maria Emilia Paladino, Diego Cortinovis, Francesco Petrella
Pleural mesothelioma is a rare and aggressive cancer that affects the pleura. In recent years, there has been increasing interest and attention in detecting and diagnosing early-stage or precancerous forms of mesothelioma because of its severe prognosis and short life expectancy at the time of diagnosis. Mesothelioma in situ represents a clear opportunity to improve and innovate the diagnostic approach and the multimodality treatment of mesothelioma: the diagnosis of pleural mesothelioma at the 'in-situ phase' means early disease detection and thus paves the way to new possible curable strategies...
March 11, 2024: European Journal of Cancer Prevention
https://read.qxmd.com/read/38545076/implementation-of-a-high-resolution-high-contrast-magnetic-resonance-imaging-protocol-with-extended-delayed-phases-for-peritoneal-mesothelioma
#37
JOURNAL ARTICLE
Milica Medved, Hunter D D Witmer, Ankit Dhiman, Yaniv Berger, Scott K Sherman, Enal S Hindi, Samuel G Armato, Ingrid S Reiser, Aytekin Oto, Roger M Engelmann, Hedy L Kindler, Nisa C Oren, Carla B Harmath, Kiran K Turaga
BACKGROUND: Imaging of peritoneal malignancies using conventional cross-sectional imaging is challenging, but accurate assessment of peritoneal disease burden could guide better selection for definitive surgery. Here we demonstrate feasibility of high-resolution, high-contrast magnetic resonance imaging (MRI) of peritoneal mesothelioma and explore optimal timing for delayed post-contrast imaging. METHODS: Prospective data from inpatients with malignant peritoneal mesothelioma (MPM), imaged with a novel MRI protocol, were analyzed...
March 15, 2024: Quantitative Imaging in Medicine and Surgery
https://read.qxmd.com/read/38538248/-research-progress-on-pathogenesis-of-malignant-mesothelioma
#38
JOURNAL ARTICLE
W Mei, Y P Zhang, S J Yang
The occurrence of malignant mesothelioma is related to exposure of asbestos. And many researchers have conducted in-depth analysis of the molecular changes of mesothelioma, showed that its molecular characteristics were chromosome changes, including chromosome rearrangement, gene mutation and gene deletion. Recent studies have strengthened our understanding of molecular characterization of mesothelioma, such as targeted mutations of tumor suppressor genes, differential gene expression, changes of miRNA and signal pathways...
March 20, 2024: Chinese Journal of Industrial Hygiene and Occupational Diseases
https://read.qxmd.com/read/38538239/-survival-analysis-of-37-cases-of-malignant-mesothelioma
#39
JOURNAL ARTICLE
Z Z Wang, J J Zhang, P P Song, H Zhang, L M Luo, T Luan
Objective: To explore the relationship between clinicopathological features, treatment and prognosis of patients with malignant mesothelioma, and provide theoretical basis for the prevention and treatment of malignant mesothelioma. Methods: In November 2022, the clinical data of 37 patients with malignant mesothelioma diagnosed in Qingdao Central Hospital from July 2014 to November 2022 were retrospectively analyzed, and the prognostic factors were analyzed by Kaplan-Meier and log-rank tests. Results: The median age of the 37 patients was 66 years old, all patients were confirmed by pathology...
March 20, 2024: Chinese Journal of Industrial Hygiene and Occupational Diseases
https://read.qxmd.com/read/38532642/kinetically-controlled-polyelectrolyte-complex-assembly-of-microrna-peptide-nanoparticles-toward-treating-mesothelioma
#40
JOURNAL ARTICLE
Caleb F Anderson, Anand Singh, Tyler Stephens, Chuong D Hoang, Joel P Schneider
Broad size distributions and poor long-term colloidal stability of microRNA-carrying nanoparticles, especially those formed by polyelectrolyte complexation, represent major hurdles in realizing their clinical translation. Herein, peptide design is used alongside optimized flash nanocomplexation (FNC) to produce uniform peptide-based miRNA particles of exceptional stability that display anticancer activity against mesothelioma in vitro and in vivo. Modulating the content and display of lysine-based charge from small intrinsically disordered peptides used to complex miRNA proved essential in achieving stable colloids...
March 26, 2024: Advanced Materials
keyword
keyword
267
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.